newsfilter
← Latest News
GlobeNewswire·

BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting

BICX104 was Well Tolerated with No Serious Adverse Events Reported and Achieved 84 Days of Therapeutic Naltrexone Plasma ConcentrationsBICX104 Subjects Experienced Better 84-Day Treatment Adherence Than